Veloxis is a specialty pharmaceutical company with a singular focus on meeting the needs of the global transplant community. Our roots stem from an endeavor launched by Danish pharmaceutical company H. Lundbeck A/S to enhance the delivery of a specific class of drugs. This led to a proprietary formulation technology, MeltDose®, which is designed to potentially address issues of bioavailability of poorly water-soluble drugs. To commercialize the technology, LifeCycle Pharma A/S was formed in June 2002. In July 2011, LifeCycle Pharma became Veloxis Pharmaceuticals A/S. Veloxis is listed on NASDAQ OMX Copenhagen A/S (OMX: VELO). Veloxis is an international company with headquarters in Hørsholm, Denmark, and a fully owned subsidiary in Edison, New Jersey, USA.
BUSINESS DEVELOPMENT CONTACT:
Alastair McEwan, EVP, COO